ATHE — ALTERITY THERAPEUTICS LTD
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1131343 ·
Australia
Last close
$4.42
Market Cap
$80.12M
52W High
$5.89
52W Low
$3.84
ADV30
18,767
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 56,918,905 | 49,200,547 | 2,650,906 |
| Jun 2025 | — | — | — | — | 46,026,360 | 33,158,642 | 3,623,274 |
| Dec 2024 | — | — | — | — | 10,546,933 | 4,536,559 | 2,760,926 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-234,379,461
Inventory
—
Receivables
$6,842,493
ST Investments
$7,500,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,636,421
EBITDA
$-17,550,620
Free Cash Flow
$-10,609,269
Enterprise Value
$-47,501,600
Total Cash
$49,200,548
Total Debt
$98,449
Shares Out
18,125,694
Trailing EPS
$-0.56
Book Value
$104.19
ROE
-47.0%
ROA
-32.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 0 | -12,333,683 | -12,147,828 | 46,026,360 | 3,623,274 | — | -11,451,248 |
| Jun 2024 | 0 | -19,402,317 | -19,123,464 | 19,223,743 | 5,425,686 | — | -12,605,824 |
| Jun 2023 | 0 | -14,368,225 | -13,806,515 | 27,317,636 | 4,504,727 | — | -20,035,837 |
| Jun 2022 | 0 | -15,137,322 | -12,847,061 | 41,362,611 | 5,894,020 | — | -12,337,274 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.22
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LFVN | Lifevantage Corp | $81.12M | $6.43 | — |
| GOSS | Gossamer Bio, Inc. | $83.10M | $0.17 | — |
| TELO | Telomir Pharmaceuticals, Inc. | $83.22M | $1.21 | — |
| PRNAF | ALTERITY THERAPEUTICS LTD | $76.13M | $0.35 | — |
| MAIA | MAIA Biotechnology, Inc. | $76.00M | $1.25 | — |
News headlines (Yahoo Finance, 1h cache)
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
2026-07-30 11:25 · Yahoo
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
2026-07-21 11:25 · Yahoo
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
2026-07-07 11:05 · Yahoo
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?
2026-06-19 13:40 · Yahoo
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
2026-06-09 11:05 · Yahoo
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
2026-05-19 11:25 · Yahoo
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
2026-05-11 11:25 · Yahoo
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
2026-05-07 11:25 · Yahoo
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
2026-04-30 11:25 · Yahoo
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
2026-04-27 11:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.